Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$6.15
+5.1%
$5.01
$3.42
$7.20
$345.72M1.821.52 million shs1.17 million shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$12.87
+4.0%
$11.84
$8.04
$30.39
$349.05M2.3438,544 shs436,301 shs
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
$5.93
+3.7%
$4.65
$3.56
$12.92
$334.65M0.39370,866 shs251,340 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.20
$1.21
$0.97
$5.07
$82.05M-0.12436,105 shs363,060 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.00%+2.27%+14.04%+33.26%+1.92%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%-3.21%+6.27%-12.57%-60.06%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
0.00%-4.51%+44.44%-11.73%-37.49%
Zura Bio Limited stock logo
ZURA
Zura Bio
0.00%-4.76%+8.11%-11.76%-68.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.2896 of 5 stars
0.02.00.00.01.60.80.6
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.2106 of 5 stars
4.60.00.00.03.52.50.6
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
2.1546 of 5 stars
3.62.00.00.02.81.70.0
Zura Bio Limited stock logo
ZURA
Zura Bio
2.6328 of 5 stars
3.61.00.00.03.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
3.67
Strong BuyN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$53.50315.70% Upside
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3.25
Buy$30.00405.90% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.331,094.44% Upside

Current Analyst Ratings Breakdown

Latest ZURA, ARCT, ACB, and ATXS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/14/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
4/29/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$47.00
4/10/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00
4/3/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$320.81M1.08$0.23 per share26.35$8.18 per share0.75
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$131.27M2.66N/AN/A$10.42 per share1.24
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/A$3.33 per shareN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$1.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
-$48.62M$0.05123.0213.98N/A0.42%0.59%0.42%6/18/2025 (Estimated)
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$29.73M-$2.53N/AN/AN/A-36.39%-22.39%-14.81%8/4/2025 (Estimated)
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$72.89M-$1.87N/AN/AN/AN/A-43.58%-29.36%8/11/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)

Latest ZURA, ARCT, ACB, and ATXS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025Q4 2025
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
$0.11N/AN/AN/A$88.85 millionN/A
5/13/2025Q1 2025
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
-$0.48-$0.58-$0.10-$0.58N/AN/A
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
3/25/2025Q4 2024
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.08+$0.09-$0.08N/A$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$0.715.56%N/AN/A N/A
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.07
3.30
1.60
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/A
4.76
4.76
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
N/A
22.38
22.38
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
10.36
10.36

Institutional Ownership

CompanyInstitutional Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
47.63%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
98.98%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
0.01%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
16.60%
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
4.50%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aurora Cannabis Inc. stock logo
ACB
Aurora Cannabis
1,34056.21 million54.85 millionOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.94 millionOptionable
Astria Therapeutics, Inc. stock logo
ATXS
Astria Therapeutics
3056.43 million54.80 millionOptionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million50.86 millionOptionable

Recent News About These Companies

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aurora Cannabis stock logo

Aurora Cannabis NASDAQ:ACB

$6.15 +0.30 (+5.13%)
Closing price 04:00 PM Eastern
Extended Trading
$6.17 +0.02 (+0.31%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$12.87 +0.49 (+3.96%)
Closing price 04:00 PM Eastern
Extended Trading
$13.10 +0.24 (+1.83%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Astria Therapeutics stock logo

Astria Therapeutics NASDAQ:ATXS

$5.93 +0.21 (+3.67%)
Closing price 04:00 PM Eastern
Extended Trading
$5.93 0.00 (0.00%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.20 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 +0.03 (+2.50%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.